Articles related to Oncology, Medical

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.

A digital patient navigation platform exceeded standard web-based engagement benchmarks in connecting melanoma patients with subspecialty oncology care across an academic center and regional health system network, though transition to multidisciplinary care remained more common at the academic site.

A case of chemotherapy-induced menopause left unmanaged for six years prompted a physician’s pointed critique of survivorship care failures, highlighting the clinical and legal stakes of untreated premature ovarian insufficiency following gonadotoxic therapy.